Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK
Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.
Authors
- Nele Debackere
- Beatrice Osumili (ORCID: https://orcid.org/0000-0002-5862-9325)
- Naresh Kanumilli (ORCID: https://orcid.org/0000-0003-3080-7713)
- Juliette Cattin
- Jerome Evans
- Joanne Webb
- Piotr Nowakowski
- Barnaby Hunt
- Mike Buckingham
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1080/13696998.2026.2631920
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00